Compare NEOS S&P 500 High Income ETF (SPYI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NEOS S&P 500 High Income ETF vs State Street SPDR S&P Biotech ETF — how do they compare? NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B), while State Street SPDR S&P Biotech ETF trades at $153.87 (market cap $10.11B). The key difference: NEOS S&P 500 High Income ETF is the larger of the two by market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NEOS S&P 500 High Income ETF for 58 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SPYI | XBI | |
|---|---|---|
Market Cap | $12.50B | $10.11B |
Volume | 3,058,962 | 12,903,266 |
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $54.42 | $169.55 |
52-Week Low | $47.98 | $104.99 |
Typical Hold Time | 58 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPYI trades at $54.095 with a modest 0.16% daily gain, showing bullish technical momentum with strong moving average signals. The ETF maintains consistent monthly dividend distributions around $0.53-0.54 per share, targeting income-focused investors. Recent news highlights SPYI's popularity among retirement portfolios while raising concerns about principal erosion from covered call strategies.
The outlook remains mixed - strong technicals and high yield appeal support near-term stability, but long-term capital preservation risks from the covered call strategy warrant caution. Income investors benefit from consistent distributions, though growth-oriented investors may find the strategy limiting during bull markets.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
